Dashboard
1
Poor Management Efficiency with a low ROCE of 11.74%
- The company has been able to generate a Return on Capital Employed (avg) of 11.74% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -8.46% and Operating profit at -12.85% over the last 5 years
3
Negative results in Mar 25
4
With ROE of 3.29%, it has a fair valuation with a 1.38 Price to Book Value
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 9,933 Million (Large Cap)
42.00
NA
1.57%
-0.37
3.64%
1.29
Revenue and Profits:
Net Sales:
466 Million
(Quarterly Results - Sep 2025)
Net Profit:
118 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.59%
0%
-10.59%
6 Months
-17.89%
0%
-17.89%
1 Year
-22.59%
0%
-22.59%
2 Years
-9.73%
0%
-9.73%
3 Years
-37.48%
0%
-37.48%
4 Years
-34.2%
0%
-34.2%
5 Years
-9.48%
0%
-9.48%
China Resources Boya Bio-pharmaceutical Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-8.46%
EBIT Growth (5y)
-12.85%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.41
Sales to Capital Employed (avg)
0.28
Tax Ratio
17.37%
Dividend Payout Ratio
40.65%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.74%
ROE (avg)
4.93%
Valuation key factors
Factor
Value
P/E Ratio
42
Industry P/E
Price to Book Value
1.38
EV to EBIT
31.67
EV to EBITDA
19.47
EV to Capital Employed
1.62
EV to Sales
4.14
PEG Ratio
0.96
Dividend Yield
1.53%
ROCE (Latest)
5.12%
ROE (Latest)
3.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
466.20
471.90
-1.21%
Operating Profit (PBDIT) excl Other Income
39.00
109.90
-64.51%
Interest
0.20
0.40
-50.00%
Exceptional Items
11.40
12.30
-7.32%
Consolidate Net Profit
117.60
86.10
36.59%
Operating Profit Margin (Excl OI)
83.70%
143.20%
-5.95%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is -1.21% vs -11.94% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 36.59% vs -38.19% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
1,727.90
2,642.20
-34.60%
Operating Profit (PBDIT) excl Other Income
539.30
642.10
-16.01%
Interest
1.10
0.80
37.50%
Exceptional Items
-18.20
-241.00
92.45%
Consolidate Net Profit
396.50
248.10
59.81%
Operating Profit Margin (Excl OI)
244.50%
199.90%
4.46%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -34.60% vs -3.84% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 59.81% vs -44.31% in Dec 2023
About China Resources Boya Bio-pharmaceutical Group Co., Ltd. 
China Resources Boya Bio-pharmaceutical Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






